• Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates.
• The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda.
• These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market.

Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh attention as it moves two key assets into the regulatory spotlight while pushing ahead with late stage studies alongside major partners. The stock closed at $81.49, with a very large 3 year return of 404.0% and a 1 year return of 110.7%, even as returns over the past week, month, and year to date show declines of 3.6%, 4.4%, and 6.5% respectively. That mix of strong multi year performance and recent pullbacks gives investors a lot to weigh as these new milestones land.

With NDAs now submitted for Icotrokinra and Rusfertide and multiple Phase 3 readouts on the horizon, the story is increasingly centered on clinical and regulatory execution. For you as an investor, the key questions are likely to revolve around how these partners, Johnson & Johnson and Takeda, help carry the programs through late stage development and how upcoming data might reshape perceptions of risk and opportunity in the Protagonist Therapeutics pipeline.

Stay updated on the most important news stories for Protagonist Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Protagonist Therapeutics.

Quick Assessment

• ✅ Price vs Analyst Target: At US$81.49, Protagonist Therapeutics trades about 20% below the US$101.92 analyst target.
• ✅ Simply Wall St Valuation: Our model suggests the shares trade roughly 76.7% below estimated fair value.
• ❌ Recent Momentum: The 30 day return of about 4.4% decline shows short term weakness despite recent NDA news.

There is only one way to know the right time to buy, sell or hold Protagonist Therapeutics. Head to the Simply Wall St company report for the latest analysis of Protagonist Therapeutics's Fair Value.

Key Considerations

• 📊 Dual NDAs and advancing Phase 3 programs with Johnson & Johnson and Takeda put regulatory decisions and partner execution at the center of the story.
• 📊 With a P/E of about 111 versus the Biotechs industry average of roughly 22, and a price below analyst targets, you may want to watch how earnings and NDA progress line up with that valuation.
• ⚠️ Net margin has eased from 52.8% to 21.9% and there has been significant insider selling in the past 3 months, which some investors will track closely as these catalysts unfold.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Protagonist Therapeutics analysis. Alternatively, you can check out the community page for Protagonist Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.